(+)-トラマドール

1-(3-メトキシフェニル)-2β-[(ジメチルアミノ)メチル]シクロヘキサン-1β-オール · (1R,2R)-2-(ジメチルアミノメチル)-1-(3-メトキシフェニル)シクロヘキサノール · (R)-トラマドール · 1α-(3-メトキシフェニル)-2β-(ジメチルアミノメチル)シクロヘキサン-1β-オール · (1R,2R)-2-[(ジメチルアミノ)メチル]-1-(3-メトキシフェニル)シクロヘキサン-1-オール · trans-トラマドール · (+)-トラマドール · (1R)-1-(3-メトキシフェニル)-2β-[(ジメチルアミノ)メチル]シクロヘキサン-1β-オール

https://huagongshe.com/ja/chemical/33741

識別子と物理属性

CAS No.	123154-38-1
分子式	C16H25NO2
平均分子量	263.37 g/mol
SMILES	COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1
InChIKey	TVYLLZQTGLZFBW-ZBFHGGJFSA-N
PubChem CID	33741
ChEMBL	CHEMBL1066
ChEBI	CHEBI:75725
EC No.	248-319-6
DTXSID	DTXSID401167150
現地名	(+)-トラマドール

化学・物理的性質

XLogP	2.6
極性表面積	32.7
水素結合供与体数	1
水素結合受容体数	3
回転可能結合数	4
重原子数	19
形式電荷	0
複雑度	282
物質分類	Pharmaceutical
医薬品	DEA NFLIS-Drug Category -> Narcotic AnalgesicsPharmaceuticals -> AnalgesicsPharmaceuticals -> Listed in ZINC15Pharmaceuticals -> Used in SwitzerlandPharmaceuticals -> Synthetic Cannabinoids or Psychoactive Compounds
LogP（分配係数）	2.4
溶解度	Soluble7.50e-01 g/L>39.5 [ug/mL] (The mean of the results at pH 7.4)
Human Drugs	Breast FeedingLactationMilk, HumanAnalgesics, OpioidNarcoticsPharmaceuticals
Endocrine Disruptors	Potential endocrine disrupting compound
Decomposition	When heated to decomposition it emits very toxic fumes of /nitrogen oxides/.
融点	178-181 °C180 - 181 °C
Physical Description	Solid
Stability/Shelf Life	Stable under recommended storage conditions. /Tramadol hydrochloride/
Dissociation Constants	9.41pKa1 = 9.23 (tertiarary amine)pKa2= 13.08 (alcohol)
貯蔵条件	Refrigerator

化学的特性

(+)-trans-Tramadol free base is Light Yellow Oil

安全性と法規制

GHS 分類	DangerH300 (28.6%): Fatal if swallowed [Danger Acute toxicity, oral]P261, P264, P264+P265, P270, P271, P280, P301+P316, P302+P352, P304+P340, P305+P351+P338, P316, P317, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 7 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.WarningH302: Harmful if swallowed [Warning Acute toxicity, oral]
規制情報	Status: Active Update: 29-05-2018 https://echa.europa.eu/registration-dossier/-/registered-dossier/24188Tramadol: Does not have an individual approval but may be used under an appropriate group standard
FDA 要件	The Approved Drug Products with Therapeutic Equivalence Evaluations identifies currently marketed prescription drug products, including tramadol hydrochloride, approved on the basis of safety and effectiveness by FDA under sections 505 of the Federal Food, Drug, and Cosmetic Act. /Tramadol hydrochloride/Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it. (b) Narcotic drugs. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below. 2-[(Dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol, its salts, optical and geometric isomers and salts of these isomers (including tramadol) is included on this list.
Special Reports	CDC Guideline for Prescribing Opioids for Chronic Pain - United States, 2016This guideline provides recommendations for primary care clinicians who are prescribing opioids for chronic pain outside of active cancer treatment, palliative care, and end-of-life care. The guideline addresses 1) when to initiate or continue opioids for chronic pain2) opioid selection, dosage, duration, follow-up, and discontinuationand 3) assessing risk and addressing harms of opioid use. CDC developed the guideline using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework, and recommendations are made on the basis of a systematic review of the scientific evidence while considering benefits and harms, values and preferences, and resource allocation. CDC obtained input from experts, stakeholders, the public, peer reviewers, and a federally chartered advisory committee. It is important that patients receive appropriate pain treatment with careful consideration of the benefits and risks of treatment options. This guideline is intended to improve communication between clinicians and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including opioid use disorder, overdose, and death.[Dowell D et al

用途

使用

(+)-trans-Tramadol free base is an analgesic. Used in the treatment of urinary incontinence.